NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
We thank all trainees for their thoughtful participation and contributions to the program. We also acknowledge our sponsors, Stem Cell Network and Lucid Scientific, whose support helped make the program accessible. We thank the Resipher team, Silke Grainger and Ghainaa Abousleiman, for their hands-on session on cellular metabolism and its applications in neuromuscular research.
We are grateful to our patient partner, Jenna Keindel, for sharing her lived experience and perspective. Her contribution highlighted the importance of open science and communicating research in ways that are accessible to patients and the broader community.
Finally, we thank our organizing team, Dr. Mireille Khacho (lead), Dr. Vahab Soleimani, Dr. Keir Menzies, Dr. Michael DeLisio, Dr. Junio Dort, Dr. Yan Burelle, Dr. Jean-Philippe Leduc-Gaudet, Dr. Emma Sutton, Rebecca Yaworski, Dr. Sally Spendiff and Ricardo Carmona, Dr. Alex Green, and Jonathan Mesiano-Crookston (patient partner), for their roles in planning and delivering the program. NMD4C remains committed to supporting trainee development and strengthening collaboration across the neuromuscular research community in Canada.
Stay tuned for photos and highlights from the event!
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.